BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12186341)

  • 1. Tibolone, blood pressure and obesity.
    Roshan J; Ganesh A
    Natl Med J India; 2002; 15(3):180. PubMed ID: 12186341
    [No Abstract]   [Full Text] [Related]  

  • 2. A case report of recurrent endometriosis following Tibolone hormone replacement therapy.
    Sundar SS; Gornall RJ; Kerr-Wilson R; Swingler GR; Kinder RB; McCarthy K
    J Obstet Gynaecol; 2007 May; 27(4):433-4. PubMed ID: 17654209
    [No Abstract]   [Full Text] [Related]  

  • 3. Complex endometrial hyperplasia in the context of tibolone administration.
    Kane SC; Quinn MA
    Aust N Z J Obstet Gynaecol; 2009 Jun; 49(3):338-9. PubMed ID: 19566575
    [No Abstract]   [Full Text] [Related]  

  • 4. Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy.
    Perez-Medina T; Bajo-Arenas J; Haya J; Sanfrutos L; Iniesta S; Bueno B; Castelo-Branco C
    Menopause; 2003; 10(6):534-7. PubMed ID: 14627862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The LIBERATE tibolone trial in breast cancer survivors.
    Speroff L
    Maturitas; 2009 May; 63(1):1-3. PubMed ID: 19327923
    [No Abstract]   [Full Text] [Related]  

  • 6. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
    Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
    Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tibolone.
    Reynir Tomas G
    Acta Obstet Gynecol Scand; 2004 Jun; 83(6):606. PubMed ID: 15144349
    [No Abstract]   [Full Text] [Related]  

  • 8. Tibolone: the risk is too high.
    Goodwin PJ
    Lancet Oncol; 2009 Feb; 10(2):103-4. PubMed ID: 19185829
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of hormone replacement therapy on mammographic findings.
    Bülbül NH; Ozden S; Dayicioglu V
    Arch Gynecol Obstet; 2003 Apr; 268(1):5-8. PubMed ID: 12673467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
    Eilertsen AL; Liestøl S; Mowinckel MC; Hemker HC; Sandset PM
    Thromb Haemost; 2007 Jun; 97(6):938-43. PubMed ID: 17549295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endometrial effects of tibolone in elderly, osteoporotic women.
    Ettinger B; Kenemans P; Johnson SR; Mol-Arts M; Van Os S; Seifert W; Verweij PJ; Cummings SR
    Obstet Gynecol; 2008 Sep; 112(3):653-9. PubMed ID: 18757665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
    Dimitrakakis C; Keramopoulos D; Vourli G; Gaki V; Bredakis N; Keramopoulos A
    Climacteric; 2005 Dec; 8(4):342-51. PubMed ID: 16390769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tibolone therapy in postmenopausal women with a history of many risk factors].
    Szántó F
    Orv Hetil; 2003 Apr; 144(15):701-4. PubMed ID: 12774429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
    Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exacerbation of adenomyosis in a postmenopausal woman taking tibolone associated with an elevation in serum CA 125.
    Davies AP; Oram D
    Br J Obstet Gynaecol; 1994 Jul; 101(7):632-3. PubMed ID: 8043545
    [No Abstract]   [Full Text] [Related]  

  • 16. Endometrial cancer--surprising reports.
    Speroff L
    Maturitas; 2005 Aug; 51(4):329-33. PubMed ID: 16039404
    [No Abstract]   [Full Text] [Related]  

  • 17. Hormone therapy and raloxifene reduce the coagulation inhibitor potential.
    Andresen MS; Eilertsen AL; Abildgaard U; Sandset PM
    Blood Coagul Fibrinolysis; 2007 Jul; 18(5):455-60. PubMed ID: 17581320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some comments on the Million Women Study.
    Neves-E-Castro M
    Climacteric; 2003 Dec; 6(4):357. PubMed ID: 15006258
    [No Abstract]   [Full Text] [Related]  

  • 19. The need for tissue selective menopausal agents.
    Eden J
    Gynecol Endocrinol; 2005 Jul; 21 Suppl 1():22-7. PubMed ID: 16112952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group.
    Kenemans P; Speroff L;
    Maturitas; 2005 May; 51(1):21-8. PubMed ID: 15883105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.